ArticleDiscover oncology2025
Gelsolin (GSN) as a key regulator in estrogen receptor-positive breast cancer: implications for prognosis, chemotherapy sensitivity, and immune infiltration.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGelsolin (GSN), a cytoskeletal regulatory protein implicated in cancer progression, remains understudied in estrogen receptor-positive breast cancer (ER + BC), particularly regarding its links to immune infiltration and drug resistance.
methodsTranscriptomic data from TCGA (616 ER + tumors, 113 normal) and Metabric (1,497 ER + cases) were analyzed. Immunohistochemistry images were sourced from the Human Protein Atlas database (HPA). Differential expression analysis (limma package), Mendelian randomization (MR) for causal inference, and colocalization (Coloc package) were employed. Drug sensitivity and immune infiltration correlations were assessed using multiple bioinformatics tools.
resultsDifferential expression revealed 303 upregulated and 715 downregulated genes. MR identified 276 eQTLs and 106 pQTLs, with GSN as a central key gene. Elevated GSN expression correlated with reduced ER + breast cancer risk (colocalization analysis: shared variant probability PP.H4.abf = 1.01%). Immunohistochemistry analysis demonstrated significantly lower GSN expression in ER + BC cases compared to normal samples, consistent with finding from TCGA cohorts. Higher GSN expression was linked to improved RFS in the Metabric (p = 0.023) and Kaplan-Meier datasets (p = 0.001). GSN expression was also associated with tumor size, age, and chemotherapy sensitivity for Cisplatin, Docetaxel, Doxorubicin, Etoposide, Gemcitabine, and Vinorelbine. Immune infiltration analysis showed a positive correlation between high GSN expression and the infiltration of naive B cells, but a reverse result was observed with M2 macrophage infiltration. GSN has potential as both a prognostic and therapeutic marker in ER + breast cancer, influencing immune response and drug sensitivity. Its low expression in tumors and survival benefits suggest it can help with risk assessment and treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.